These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 11390655)
21. The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin. Pinkas-Kramarski R; Lenferink AE; Bacus SS; Lyass L; van de Poll ML; Klapper LN; Tzahar E; Sela M; van Zoelen EJ; Yarden Y Oncogene; 1998 Mar; 16(10):1249-58. PubMed ID: 9546426 [TBL] [Abstract][Full Text] [Related]
22. Proliferation-differentiation relationships in the expression of heparin-binding epidermal growth factor-related factors and erbB receptors by normal and psoriatic human keratinocytes. Piepkorn M; Predd H; Underwood R; Cook P Arch Dermatol Res; 2003 Jul; 295(3):93-101. PubMed ID: 12768307 [TBL] [Abstract][Full Text] [Related]
23. Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells. Aguilar Z; Akita RW; Finn RS; Ramos BL; Pegram MD; Kabbinavar FF; Pietras RJ; Pisacane P; Sliwkowski MX; Slamon DJ Oncogene; 1999 Oct; 18(44):6050-62. PubMed ID: 10557094 [TBL] [Abstract][Full Text] [Related]
24. Distinct characteristics of heregulin signals mediated by HER3 or HER4. Weiss FU; Wallasch C; Campiglio M; Issing W; Ullrich A J Cell Physiol; 1997 Nov; 173(2):187-95. PubMed ID: 9365520 [TBL] [Abstract][Full Text] [Related]
25. TOB1 is regulated by EGF-dependent HER2 and EGFR signaling, is highly phosphorylated, and indicates poor prognosis in node-negative breast cancer. Helms MW; Kemming D; Contag CH; Pospisil H; Bartkowiak K; Wang A; Chang SY; Buerger H; Brandt BH Cancer Res; 2009 Jun; 69(12):5049-56. PubMed ID: 19491269 [TBL] [Abstract][Full Text] [Related]
26. Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation. Elenius K; Paul S; Allison G; Sun J; Klagsbrun M EMBO J; 1997 Mar; 16(6):1268-78. PubMed ID: 9135143 [TBL] [Abstract][Full Text] [Related]
27. Stimulation of beta1-integrin function by epidermal growth factor and heregulin-beta has distinct requirements for erbB2 but a similar dependence on phosphoinositide 3-OH kinase. Adelsman MA; McCarthy JB; Shimizu Y Mol Biol Cell; 1999 Sep; 10(9):2861-78. PubMed ID: 10473632 [TBL] [Abstract][Full Text] [Related]
28. The heregulin/human epidermal growth factor receptor as a new growth factor system in melanoma with multiple ways of deregulation. Stove C; Stove V; Derycke L; Van Marck V; Mareel M; Bracke M J Invest Dermatol; 2003 Oct; 121(4):802-12. PubMed ID: 14632199 [TBL] [Abstract][Full Text] [Related]
29. Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells. Ostrander JH; Daniel AR; Lofgren K; Kleer CG; Lange CA Cancer Res; 2007 May; 67(9):4199-209. PubMed ID: 17483331 [TBL] [Abstract][Full Text] [Related]
30. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands. Carrión-Salip D; Panosa C; Menendez JA; Puig T; Oliveras G; Pandiella A; De Llorens R; Massaguer A Int J Oncol; 2012 Sep; 41(3):1128-38. PubMed ID: 22684500 [TBL] [Abstract][Full Text] [Related]
31. Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase. Gründker C; Völker P; Emons G Endocrinology; 2001 Jun; 142(6):2369-80. PubMed ID: 11356684 [TBL] [Abstract][Full Text] [Related]
32. Insulin-like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine-phosphorylated p185erbB-2. Ram TG; Dilts CA; Dziubinski ML; Pierce LJ; Ethier SP Mol Carcinog; 1996 Mar; 15(3):227-38. PubMed ID: 8597535 [TBL] [Abstract][Full Text] [Related]
33. Role of epidermal growth factor receptor and STAT-3 activation in autonomous proliferation of SUM-102PT human breast cancer cells. Sartor CI; Dziubinski ML; Yu CL; Jove R; Ethier SP Cancer Res; 1997 Mar; 57(5):978-87. PubMed ID: 9041204 [TBL] [Abstract][Full Text] [Related]
34. Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Gregory CW; Whang YE; McCall W; Fei X; Liu Y; Ponguta LA; French FS; Wilson EM; Earp HS Clin Cancer Res; 2005 Mar; 11(5):1704-12. PubMed ID: 15755991 [TBL] [Abstract][Full Text] [Related]
35. Src family kinases and HER2 interactions in human breast cancer cell growth and survival. Belsches-Jablonski AP; Biscardi JS; Peavy DR; Tice DA; Romney DA; Parsons SJ Oncogene; 2001 Mar; 20(12):1465-75. PubMed ID: 11313890 [TBL] [Abstract][Full Text] [Related]
36. Effects of HER2 overexpression on cell signaling networks governing proliferation and migration. Wolf-Yadlin A; Kumar N; Zhang Y; Hautaniemi S; Zaman M; Kim HD; Grantcharova V; Lauffenburger DA; White FM Mol Syst Biol; 2006; 2():54. PubMed ID: 17016520 [TBL] [Abstract][Full Text] [Related]
37. ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis. Révillion F; Lhotellier V; Hornez L; Bonneterre J; Peyrat JP Ann Oncol; 2008 Jan; 19(1):73-80. PubMed ID: 17962208 [TBL] [Abstract][Full Text] [Related]
38. Heregulin induces tyrosine phosphorylation of HER4/p180erbB4. Plowman GD; Green JM; Culouscou JM; Carlton GW; Rothwell VM; Buckley S Nature; 1993 Dec; 366(6454):473-5. PubMed ID: 7902537 [TBL] [Abstract][Full Text] [Related]
39. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Tang CK; Gong XQ; Moscatello DK; Wong AJ; Lippman ME Cancer Res; 2000 Jun; 60(11):3081-7. PubMed ID: 10850460 [TBL] [Abstract][Full Text] [Related]
40. Heregulin activation of extracellular acidification in mammary carcinoma cells is associated with expression of HER2 and HER3. Chan SD; Antoniucci DM; Fok KS; Alajoki ML; Harkins RN; Thompson SA; Wada HG J Biol Chem; 1995 Sep; 270(38):22608-13. PubMed ID: 7673253 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]